in part to the fact that it was soon established that infection with AAV is not associated with any disease, even though most humans are routinely exposed to the virus. With no compelling medical reason to study the virus, it has remained the province of a small number of parvovirologists who have been interested in its unusual molecular biology. AAV-2, the prototype strain, has a DNA genome 5 infected with the AAV vector, they show a higher survival potential. Cells incubated with virus produced a fourfold higher number of colonies compared to uninfected controls, and those that were treated with mitomycin C produced an 8-10-fold increase in the number of measurable colonies. This is the first demonstration that a genetic defect might be capable of correction by targeting human bone marrow cells with an AAV vector. Furthermore, Walsh et al. (3) suggest that because the corrected cells display higher survival than untransduced cells, the corrected cells might have a selective advantage over the patient's defective hematopoietic stem cells and be capable of repopulating a patient's bone marrow with normal cells. This strategy might be applicable to other diseases such as AIDS.
The report by Walsh et al. (3) is consistent with earlier reports that primary mouse hematopoietic cells can be successfully transduced in culture with AAV vectors carrying the neomycin phosphotransferase marker (4, 5) . It is also consistent with recent work by Flotte et al. (6) which demonstrated successful transduction of primary human and rabbit airway epithelial cells by an AAV vector carrying the cystic fibrosis transmembrane conductance regulator gene. Although these observations are encouraging, it is important to point out that, thus far, no one has shown that transduction in primary cells is permanent, that is, that the AAV vector has, in fact, integrated. Indeed, there is almost no direct evidence that AAV vectors will integrate into primary cells. In addition, in the case of bone marrow gene therapy, we will have to await the results of long term bone marrow reconstitution experiments before we can be certain whether the frequency of transduction is sufficiently high to be useful for gene therapy. Finally, as AAV is taken into the clinic we may uncover other difficulties that are not apparent from what we currently know about the biology of this interesting virus.
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